Destiny Wealth Partners’s NovoCure NVCR Stock Holding History

Destiny Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$17K	–	644
2022 Q1	$17K	Hold	200	–	–	﹤0.01%	397
2021 Q4	$15K	Hold	200	–	–	﹤0.01%	414
2021 Q3	$23K	Buy	+200	New	+$30.2K	﹤0.01%	363
2021 Q2	–	Sell	-200	Closed	-$26K	–	392
2021 Q1	$26K	Hold	200	–	–	0.01%	339
2020 Q4	$35K	Buy	+200	New	+$27.4K	0.01%	318

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Destiny Wealth Partners's NVCR Position: Q2 2022 in Review

Destiny Wealth Partners sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 200 shares — an estimated $17K sold.

Destiny Wealth Partners first reported a position in NVCR in Q4 2020 and held it in 5 quarters. The position peaked at $35K in Q4 2020. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Destiny Wealth Partners reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Destiny Wealth Partners sold 200 NovoCure shares in Q2 2022, an estimated $17K.
Destiny Wealth Partners first reported a position in NovoCure in Q4 2020 and held it in 5 quarters.
Destiny Wealth Partners's NovoCure position peaked at $35K in Q4 2020.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Destiny Wealth Partners's 13F filing for Q2 2022, filed 15 Jul 2022.